TITLE

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups

AUTHOR(S)
Hernández, Adrián V.; Westerhout, Cynthia M.; Steyerberg, Ewout W.; Loannidis, John P. A.; Bueno, Hector; White, Harvey; Theroux, Pierre; Moliterno, David J.; Armstrong, Paul W.; Califf, Robert M.; Wallentin, Lars C.; Simoons, Maarten L.; Boersma, Eric
PUB. DATE
April 2007
SOURCE
Heart;Apr2007, Vol. 93 Issue 4, p450
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To investigate whether the beneficial and harmful effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST elevation acute coronary syndromes (NSTE-ACS) depend on age. Methods: A meta-analysis of six trials of platelet glycoprotein IIb/IIIa receptor blockers in patients with NSTE-ACS (PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, GUSTO IV-ACS; n = 31 402) was performed. We applied multivariable logistic regression analyses to evaluate the drug effects on death or non-fatal myocardial infarction at 30 days, and on major bleeding, by age subgroups (<60, 60-69, 70-79, ⩾80 years). We quantified the reduction of death or myocardial infarction as the number needed to treat (NNT), and the increase of major bleeding as the number needed to harm (NNH). Results: Subgroups had 11 155 (35%), 9727 (31%), 8468 (27%) and 2049 (7%) patients, respectively. The relative benefit of platelet glycoprotein Ib/IIIa receptor blockers did not differ significantly (p=0.5) between age subgroups (OR (95% CI) for death or myocardial infarction: 0.86 (0.74 to 0.99), 0.90 (0.80 to 1.02), 0.97(0.86 to 1.10), 0.90 (0.73 to 1.16); overall 0.91 (0.86 to 0.99). ORs for major bleeding were 1.9 (1.3 to 2.8), 1.9 (1.4 to 2.7), 1 .6 (1.2 to 2.1) and 2.5 (1.5-4.1). Overall NNT was 105, and overall NNH was 90. The oldest patients had larger absolute increases in major bleeding, but also had the largest absolute reductions of death or myocardial infarction. Patients ⩾80 years had half of the NNT and a third of the NNH of patients <60 years. Conclusions: In patients with NSTE-ACS, the relative reduction of death or non-fatal myocardial infarction with platelet glycoprotein IIb/IIIa receptor blockers was independent of patient age. Larger absolute outcome reductions were seen in older patients, but with a higher risk of major bleeding. Close monitoring of these patients is warranted.
ACCESSION #
25570506

 

Related Articles

  • CORONARY ARTERY DISEASE -- PTCA.  // Current Medical Literature: Interventional Cardiology Monitor;2004, Vol. 11 Issue 1, p12 

    Discusses articles on coronary artery disease that have been published in various journals as of April 2004. "The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction," by S.J. Kernis, et al; "Meta-analysis of survival with platelet...

  • Glanzmann's thrombasthenia.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p956 

    An encyclopedia entry for "Glanzmann's thrombasthenia," which refers to a rare autosomal recessive abnormality of platelet glycoprotein IIb-IIIa that is characterized by easy bruising and epostaxis that may sometimes requires blood transfusions, is presented.

  • Review: Platelet glycoprotein IIb/IIIa blockers for PCI or acute coronary syndromes reduce death and MI but increase bleeding. Bates, Eric R. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p41 

    Focuses on a study which investigated the effect of platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention or acute coronary syndromes. Methodology of the study; Results; Comments on the outcome of the study.

  • Abatacept: A Viewpoint by Paul Emery. Emery, Paul // BioDrugs;2006, Vol. 20 Issue 1, p62 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention1. Curran, Monique P.; Keating, Gillian M. // BioDrugs;2006, Vol. 20 Issue 1, p63 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Pierangeli, S. S.; Erkan, D. // Lupus;Apr2010, Vol. 19 Issue 4, p475 

    Persistently positive antiphospholipid antibodies in association with thromboses and/or pregnancy morbidity is the hallmark of the antiphospholipid syndrome. The management of antiphospholipid antibody-positive patients has been focused on utilizing anti-thrombotic medications such as heparin or...

  • The Relevance of Platelet Glycoprotein GP IIb/IIIa Polymorphism to Anti-platelets Response in Acute Coronary Syndrome. Naye, Omnia; Sobhy, Mohamed; Baraka, Azza; El Samak, Mohamed; Kader, Sherine Abdel // Annual International Conference on Advances in Biotechnology (Bi;2013, p54 

    The era of pharmacogenomics is intervening in cardiovascular therapeutic armamentarium. In this respect, the potential implication of P1A gene variants of GPIIIa subunit of platelet membrane GP IIb/IIIa as a genetic risk factor provocateur and/or as a therapeutic outcome modulator to...

  • Abatacept: A Viewpoint by Maxime Dougados. Dougados, Maxime // BioDrugs;2006, Vol. 20 Issue 1, p62 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway. Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty.  // New England Journal of Medicine;4/7/94, Vol. 330 Issue 14, p956 

    Background: Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3 Fab) directed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics